Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy
Authors
Keywords
-
Journal
GLYCOBIOLOGY
Volume 27, Issue 8, Pages 691-695
Publisher
Oxford University Press (OUP)
Online
2017-05-19
DOI
10.1093/glycob/cwx047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells
- (2016) Masanori Wakisaka et al. PLoS One
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional expression of sodium-glucose transporters in cancer
- (2015) Claudio Scafoglio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
- (2013) M. A. Abdul-Ghani et al. DIABETES
- Regional distribution of SGLT activity in rat brain in vivo
- (2012) Amy S. Yu et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2
- (2010) Charles S. Hummel et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
- The Mesangial Cell Revisited: No Cell Is an Island
- (2009) D. Schlondorff et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Lack of A1 Adenosine Receptors Augments Diabetic Hyperfiltration and Glomerular Injury
- (2008) R. Faulhaber-Walter et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started